Administration of lactobacillus casei and bifidobacterium bifidum ameliorated hyperglycemia, dyslipidemia, and oxidative stress in diabetic rats

Abstract

Background:The present work was planned to evaluate the antihyperglycemic, lipid-lowering, and antioxidant effect of Lactobacillus casei and Bifidobacterium bifidum in streptozotocin (STZ)-induced diabetic rats.Methods:Single daily dose of 1 × 107 cfu/ml of L. casei and B. bifidum alone and in combination of both was given to Wistar rats orally by gavaging for 28 days. Glucose tolerance test, fasting blood glucose (FBG), lipid profile, and glycosylated hemoglobin (HbA1c) were measured from blood. Glycogen from thigh muscles and liver and oxidative stress parameters from pancreas were analyzed.Results:Administration of L. casei and B. bifidum alone and in combination of both to diabetic rats decreased serum FBG (60.47%, 55.89%, and 56.49%, respectively), HbA1c (28.11%, 28.61%, and 28.28%), total cholesterol (171.69%, 136.47%, and 173.58%), triglycerides (9.935%, 8.58%, and 7.91%), low-density lipoproteins (53.27%, 53.35%, and 52.91%) and very low-density lipoproteins (10%, 8.58%, and 11.15%, respectively) and increased high-density lipoproteins (13.73%, 15.47%, and 15.47%), and insulin (19.50%, 25.80%, and 29.47%, respectively). The treatment also resulted in increase in muscle (171.69%, 136.47%, and 173.58%) and liver (25.82%, 6.63%, and 4.02%) glycogen level. The antioxidant indexes in pancreas of diabetic rats returned to normal level with reduction in lipid peroxidation (30.89%, 46.46%, and 65.36%) and elevation in reduced glutathione (104.5%, 161.34%, and 179.04%), superoxide dismutase (38.65%, 44.32%, and 53.35%), catalase (13.08%, 27%, and 31.52%), glutathione peroxidase (55.56%, 72.23%, and 97.23%), glutathione reductase (49.27%, 88.40%, and 110.86%), and glutathione-S-transferase (140%, 220%, and 246.6%, respectively) on treatment with L. casei, B. bifidum, and combination treatment.Conclusions:Administration of L. casei and B. bifidum alone and in combination of both ameliorated hyperglycemia, dyslipidemia, and oxidative stress in STZ-induced diabetic Wistar rats.

Bifidobacterium bifidumTMC3115 ameliorates milk protein allergy in by affecting gut microbiota: A randomized double‐blind control trial

“…In comparison with nonallergic infants, intestinal Lactobacillus and Bifidobacterium and Lactobacillus are disappeared, and Enterobacteriaceae and Staphylococcus aureus are colonized more in some sick infants. In addition, B. bifidum has been found to have many health promoting properties, including anticancer (Heydari et al, 2018), antidiabetic (Sharma et al, 2016), anti-lipid accumulation (Wang et al, 2018), anti-inflammation (Philippe et al, 2011;Wang et al, 2016), and affect the profile of gut microbiota (Wang et al, 2019) so on. B. bifidum may have beneficial effects on CMPA infants by effecting gut microbiota.…”

Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes

“…infantis, Lactobacillus, Streptococcus, Pediococcus , and Lactococcus species ( 137 ). L. gasseri , Lactobacillus helveticus , Lactobacillus casei , and Bifidobacterium bifidum probiotic reduce fasting blood glucose levels with HbA1c ( 138 – 140 ). Mechanistically, these probiotics have been shown to have antioxidant and immunomodulatory effects by reducing oxidative stress ( 140 ), reducing inflammatory molecules, and inhibiting effector functions of CD4 + T-cells ( 142 ), which may influence on the reducing blood glucose levels and T2D risk.…”

Metformin and Its Benefits in Improving Gut Microbiota Disturbances in Diabetes Patients

“…Oral supplementation of L. casei and B. bifidum, which are frequently used as a probiotic treatment option, alone and in combination, has been shown to improve insulin resistance (decreased fasting blood glucose, decrease HbA1C) and lower the serum lipid levels by enhancing short-chain fatty acids production, and thus improving the outcome of T2D patients [46].…”